发布求助
文献互助 智能选刊 最新文献

US neurology最新文献

筛选
英文 中文
Cenobamate—The New Kid on the Block, Teaching More About Epilepsy Than Just Offering a New Treatment for Seizures 小奥巴马——这个街区的新人，教授更多关于癫痫的知识，而不仅仅是为癫痫发作提供一种新的治疗方法
US neurology Pub Date : 2020-01-01 DOI: 10.17925/USN.2020.16.2.85
R. Beran
{"title":"Cenobamate—The New Kid on the Block, Teaching More About Epilepsy Than Just Offering a New Treatment for Seizures","authors":"R. Beran","doi":"10.17925/USN.2020.16.2.85","DOIUrl":"https://doi.org/10.17925/USN.2020.16.2.85","url":null,"abstract":"<p />","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"16 1","pages":"85"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67612222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sudden Unexpected Death in Epilepsy Counseling—An American Epilepsy Society Position Statement 癫痫猝死咨询——美国癫痫协会立场声明
US neurology Pub Date : 2020-01-01 DOI: 10.17925/usn.2020.16.1.13
W. Gaillard
{"title":"Sudden Unexpected Death in Epilepsy Counseling—An American Epilepsy Society Position Statement","authors":"W. Gaillard","doi":"10.17925/usn.2020.16.1.13","DOIUrl":"https://doi.org/10.17925/usn.2020.16.1.13","url":null,"abstract":"<p />","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"16 1","pages":"13"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67612386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Group Visit Model—A Promising Option for Clinical Care Delivery in Patients with Chronic Migraine 组访模式-慢性偏头痛患者临床护理服务的一个有希望的选择
US neurology Pub Date : 2020-01-01 DOI: 10.17925/usn.2020.16.1.19
L. Wolf, Larisa Syrow
{"title":"The Group Visit Model—A Promising Option for Clinical Care Delivery in Patients with Chronic Migraine","authors":"L. Wolf, Larisa Syrow","doi":"10.17925/usn.2020.16.1.19","DOIUrl":"https://doi.org/10.17925/usn.2020.16.1.19","url":null,"abstract":"<p />","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"18 1","pages":"19"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67612440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Siponimod—A Selective Sphingosine-1-phosphate Modulator for Secondary Progressive Multiple Sclerosis siponimoda选择性鞘氨醇-1-磷酸调节剂治疗继发性进行性多发性硬化
US neurology Pub Date : 2020-01-01 DOI: 10.17925/USN.2020.16.2.99
J. Thornton, A. Harel
{"title":"Siponimod—A Selective Sphingosine-1-phosphate Modulator for Secondary Progressive Multiple Sclerosis","authors":"J. Thornton, A. Harel","doi":"10.17925/USN.2020.16.2.99","DOIUrl":"https://doi.org/10.17925/USN.2020.16.2.99","url":null,"abstract":"Over the past decade, there has been a rapid expansion of disease-modifying therapies for multiple sclerosis (MS), which exhibit a variety of different mechanisms of action. While the non-selective sphingosine-1-phosphate (S1P) receptor modulator fingolimod has been available for a decade, two novel selective S1P receptor modulators, siponimod and ozanimod, have been recently approved by the US Food and Drug Adminstration for use in \"active\" secondary progressive MS (SPMS). Siponimod, the subject of this article, is the only S1P receptor modulator studied in both relapsing remitting MS and SPMS. In this article, we review the clinical trial data regarding use of this medication and the implications for use in patients with SPMS.","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"16 1","pages":"99"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67612276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Porphyria-induced Recurrent Quadriplegia Misdiagnosed as Guillain–Barré Syndrome 卟啉引起的复发性四肢瘫痪误诊为格林-巴利综合征
US neurology Pub Date : 2020-01-01 DOI: 10.17925/usn.2020.16.1.66
N. Rad, S. Beydoun
{"title":"Porphyria-induced Recurrent Quadriplegia Misdiagnosed as Guillain–Barré Syndrome","authors":"N. Rad, S. Beydoun","doi":"10.17925/usn.2020.16.1.66","DOIUrl":"https://doi.org/10.17925/usn.2020.16.1.66","url":null,"abstract":"Introduction: Acute intermittent porphyria is the most common type of hepatic porphyria and a well-described, rare cause of neuropathy. Porphyric neuropathy can be a challenging diagnosis as neurological manifestations can be similar to Guillain–Barré syndrome. This case report describes a patient with recurrent weakness after infection, which was ultimately diagnosed as porphyric neuropathy. Case presentation: A 65-year-old female of Hispanic ethnicity developed acute respiratory failure and quadriplegia. She had a similar presentation several months prior and initially was diagnosed with an acute motor axonal neuropathy variant of Guillain–Barré syndrome. Given the recurrent attacks, tea-colored urine, dysautonomia, and syndrome of inappropriate secretion of antidiuretic hormone, acute intermittent porphyria was considered in the differential diagnosis. Urinary porphobilinogen, delta-aminolevulinic acid, and uroporphyrin were measured and found to be elevated, leading to the diagnosis of porphyria. Gene tests for eight different types of porphyria were negative. Although mutations could not be identified in this patient, acute intermittent porphyria could not be excluded because of the acute attacks and the biochemical abnormality correlates. Conclusions: Even though porphyric neuropathy can be a challenging diagnosis, accurate diagnosis is crucial to avoid permanent damage to peripheral nerves and prevent life-threatening attacks.","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"16 1","pages":"66"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67612600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Neuropathy Associated with Hereditary Transthyretin Amyloidosis—Diagnosis and Management 遗传性甲状腺转蛋白淀粉样变相关的神经病变-诊断和治疗
US neurology Pub Date : 2020-01-01 DOI: 10.17925/USN.2020.16.2.103
S. Živković
{"title":"Neuropathy Associated with Hereditary Transthyretin Amyloidosis—Diagnosis and Management","authors":"S. Živković","doi":"10.17925/USN.2020.16.2.103","DOIUrl":"https://doi.org/10.17925/USN.2020.16.2.103","url":null,"abstract":"<p />","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"53 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67612607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypervigilance in the Detection of Early Complex Regional Pain Syndrome, Type 1/Reflex Sympathetic Dystrophy—An Underutilized Tool in Treatment 1型反射性交感神经营养不良——一种未充分利用的治疗工具——在早期复杂区域性疼痛综合征中的高警惕性检测
US neurology Pub Date : 2020-01-01 DOI: 10.17925/usn.2020.16.1.43
R. Knobler
{"title":"Hypervigilance in the Detection of Early Complex Regional Pain Syndrome, Type 1/Reflex Sympathetic Dystrophy—An Underutilized Tool in Treatment","authors":"R. Knobler","doi":"10.17925/usn.2020.16.1.43","DOIUrl":"https://doi.org/10.17925/usn.2020.16.1.43","url":null,"abstract":"<p />","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67612546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in the Treatment of Neuromyelitis Optica Spectrum Disorders 视谱障碍神经脊髓炎的治疗进展
US neurology Pub Date : 2020-01-01 DOI: 10.17925/usn.2020.16.1.38
R. Brandstadter, A. Bar-Or
{"title":"Advances in the Treatment of Neuromyelitis Optica Spectrum Disorders","authors":"R. Brandstadter, A. Bar-Or","doi":"10.17925/usn.2020.16.1.38","DOIUrl":"https://doi.org/10.17925/usn.2020.16.1.38","url":null,"abstract":"Neuromyelitis optica spectrum disorder (NMOSD) encompasses inflammatory central nervous system diseases, in which severe relapses of demyelination may result in significant long-term neurologic disability. Recently, three novel immunotherapies have emerged with positive results from phase III randomized trials for relapse reduction in NMOSD. Eculizumab (complement inhibitor) added to stable immunosuppressant therapy significantly reduced the risk of relapse in patients with aquaporin-4 immunoglobulin G (AQP4-IgG)-seropositive NMOSD when compared with addition of placebo, but did not demonstrate a change in disability outcomes. Inebilizumab (anti-CD19 antibody targeting B cells) monotherapy significantly increased the time to first NMOSD attack when compared with placebo, and conferred favorable disability outcomes (reduction in disability progression) and fewer NMOSD-associated inpatient hospitalizations. Satralizumab (interleukin-6 receptor inhibitor), added to baseline immunosuppressant therapy, lowered the risk of NMOSD relapse, when compared with adding to placebo, in a study including adolescents. Safety signals emerged in each trial, including rare deaths in the eculizumab and inebilizumab trials. Individual selection of the best preventative therapy for patients will require careful consideration of several factors including AQP4-IgG serostatus, previous immunotherapies, medical comorbidities, and physician and patient preferences. Further work is needed to determine long-term efficacy and safety, but these immunotherapies have formally expanded the armamentarium for treatment of this rare and severe central nervous system neuroinflammatory disorder.","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"16 1","pages":"38"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67612511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimal Approaches to Skin Preparation Prior to Neurosurgery 神经外科手术前皮肤准备的最佳方法
US neurology Pub Date : 2020-01-01 DOI: 10.17925/USN.2010.06.02.14
Erin Graves, Lauren E. Stone, C. Loftus
{"title":"Optimal Approaches to Skin Preparation Prior to Neurosurgery","authors":"Erin Graves, Lauren E. Stone, C. Loftus","doi":"10.17925/USN.2010.06.02.14","DOIUrl":"https://doi.org/10.17925/USN.2010.06.02.14","url":null,"abstract":"<p />","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67606616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Zuranolone—An Investigational Oral Neuroactive Steroid and Positive Allosteric Modulator of GABA Type A Receptors for Postpartum Depression and Major Depressive Disorder 口服神经活性类固醇和GABA型A受体阳性变构调节剂治疗产后抑郁和重度抑郁障碍的研究
US neurology Pub Date : 2020-01-01 DOI: 10.17925/USN.2020.16.2.81
H. Gunduz-Bruce
{"title":"Zuranolone—An Investigational Oral Neuroactive Steroid and Positive Allosteric Modulator of GABA Type A Receptors for Postpartum Depression and Major Depressive Disorder","authors":"H. Gunduz-Bruce","doi":"10.17925/USN.2020.16.2.81","DOIUrl":"https://doi.org/10.17925/USN.2020.16.2.81","url":null,"abstract":"Support: No funding was received in the publication of this article. Altered neurotransmission of γ-aminobutyric acid (GABA) has been implicated in the pathogenesis of depression. In this expert interview, Dr. Handan Gunduz-Bruce discusses the background and rationale for investigating zuranolone, an oral, positive allosteric modulator of GABA type A (GABAA) receptors, as a potential treatment for postpartum depression and major depressive disorder. She also provides an overview of the clinical programs that will determine zuranolone’s place in the treatment paradigm for these depressive disorders.","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"16 1","pages":"81"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67612215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信